Predictive factors associated with prolonged survival in patients with advanced non-smallcell lung cancer (NSCLC) treated with gefitinib

被引：0
|
作者：
Satouchi, Miyako
Funada, Yasuhiro
Urata, Yoshiko
Shimada, Temiko
Yoshimura, Sho
Watanabe, Hirokazu
Kurata, Takayasu
Adachi, Shuji
Takada, Yoshiki
Negoro, Shunichi
机构：
[1] Hyogo Med Ctr Adults, Akashi, Hyogo, Japan
[2] Hyogo Med Ctr Adults, Akashi, Hyogo, Japan
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [31] Gefitinib plus interleukin-2 in previously treated patients with advanced non-small-cell lung cancer (NSCLC)
    Longarini, Raffaella
    Buti, Sebastiano
    Bosio, Giancarlo
    Brighenti, Matteo
    Porzio, Rosa
    Negri, Federica
    Passalacqua, Rodolfo
    ANNALS OF ONCOLOGY, 2007, 18 : 30 - 30
  • [32] PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED ERLOTINIB/GEFITINIB WHO FAILED PREVIOUS CHEMOTHERAPY
    Madolangan, Jamaluddin
    Andarini, Sita Laksmi
    Hudoyo, Achmad
    RESPIROLOGY, 2014, 19 : 165 - 165
  • [33] Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)
    Pastina, Pierpaolo
    Nardone, Valerio
    Botta, Cirino
    Croci, Stefania
    Tini, Paolo
    Battaglia, Giuseppe
    Ricci, Veronica
    Cusi, Maria Grazia
    Gandolfo, Claudia
    Misso, Gabriella
    Zappavigna, Silvia
    Caraglia, Michele
    Giordano, Antonio
    Aldinucci, Donatella
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    Pirtoli, Luigi
    Correale, Pierpaolo
    ONCOTARGET, 2017, 8 (44) : 75904 - 75913
  • [34] Preoperative mediastinal staging in patients withcT1-3NxM0 non-smallcell lung cancer
    Steunenberg, Bastiaan E.
    Beddows, Tom P. A.
    De Groot, Hans G. W.
    Ayez, Ninos
    Van der Leest, Cor
    Aerts, Joachim G. J., V
    Veen, Eelco J.
    THORACIC CANCER, 2020, 11 (12) : 3456 - 3462
  • [35] Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib
    Chiu, Chao-Hua
    Shih, Yu-Ning
    Tsai, Chun-Ming
    Liou, Jia-Ling
    Chen, Yuh-Min
    Perng, Reury-Perng
    LUNG CANCER, 2007, 57 (02) : 213 - 221
  • [36] Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
    Chang, Gee-Chen
    Tsai, Chun-Ming
    Chen, Kun-Chieh
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Tsung-Ying
    Lin, Ching-Pei
    Hsu, Jeng-Yuan
    Chiu, Chao-Hua
    Perng, Reury-Perng
    Yang, Pan-Chyr
    Yang, Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (06) : 520 - 525
  • [37] Association of the EGFR gene polymorphisms with clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib
    Ma, F.
    Lin, D.
    Sun, T.
    Chu, D.
    Zhang, X.
    Wang, Z.
    Wang, J.
    Shi, Y.
    Sun, Y.
    Xu, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer
    Fang, Hong
    Lin, Rong-Yan
    Sun, Ming-Xia
    Wang, Qian
    Zhao, Yu-Liang
    Yu, Jing-Lin
    Tian, Yan
    Wang, Xiao-Yun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (24) : 10967 - 10970
  • [39] Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib
    Zampa, Germano
    Moscato, Michele
    Brannigan, Brian W.
    Morabito, Alessandro
    Bell, Daphne W.
    Normanno, Nicola
    LUNG CANCER, 2008, 60 (03) : 452 - 454
  • [40] A case of ALK-associated non-smallcell lung cancer with evidence of omental metastasis 6 years after initial presentation
    Kulkarni, Sameer
    Kabbinavar, Fairooz
    Eshaghian, Shahrooz
    LUNG CANCER MANAGEMENT, 2013, 2 (03) : 199 - 204
12345